UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A 15-year perspective of the fabry outcome survey

Giugliani, R; Niu, DM; Ramaswami, U; West, M; Hughes, D; Kampmann, C; Pintos-Morell, G; ... Beck, M; + view all (2016) A 15-year perspective of the fabry outcome survey. Journal of Inborn Errors of Metabolism and Screening , 4 10.1177/2326409816666298. Green open access

[img]
Preview
Text
2326409816666298.pdf - Published version

Download (1MB) | Preview

Abstract

The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agala). Established in 2001, FOS provides long-term data on agala safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high prevalence of cardiac morbidity, and demonstrated correlations between ocular changes and Fabry disease severity. These FOS data represent a rich resource with utility not only for description of natural history/therapeutic effects but also for exploratory hypothesis testing and generation of tools for diagnosis/management, with the potential to improve future patient outcomes.

Type: Article
Title: A 15-year perspective of the fabry outcome survey
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/2326409816666298
Publisher version: https://doi.org/10.1177/2326409816666298
Language: English
Additional information: This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords: agalsidase alfa, enzyme replacement therapy, Fabry disease, Fabry Outcome Survey, outcomes
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10045911
Downloads since deposit
73Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item